| Name | Title | Contact Details |
|---|
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Danisco Venture (www.danisco.com/venture) is a corporate venture unit within Danisco A/S - one of the world's largest producers of ingredients for the food and feed industry.
The Heart and Family Health Institute of Port St. Lucie is a Port Saint Lucie, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Convacare is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hughes BioPharma Advisers is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.